ObsEva SA to Hold Investor Call to Announce Topline Results of the EDELWEISS Phase 2b Clinical Trial of Linzagolix (OBE2109) in Women with Endometriosis-Associated Pain on Monday June 18, 2018

Geneva, Switzerland and Boston, MA – June 15, 2018 – ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics…